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Genetic Relatedness, Antimicrobial
and Biocide Susceptibility Comparative Analysis
of Methicillin-Resistant and -Susceptible
Staphylococcus pseudintermedius from Portugal
Natacha Couto,1 Adriana Belas,1 Isabel Couto,2,3 Vincent Perreten,4 and Constanc¸a Pomba1
Forty methicillin-resistant and -susceptible Staphylococcus pseudintermedius (MRSP and MSSP, respectively) from
colonization and infection in dogs and cats were characterized for clonality, antimicrobial, and biocide sus-
ceptibility. MSSP were genetically more diverse than MRSP by multi-locus sequence typing and pulsed-field gel
electrophoresis. Three different spa types (t06, t02, t05) and two SCCmec types (II-III and V) were detected in the
MRSP isolates. All MRSP and two MSSP strains were multidrug-resistant. Several antibiotic resistance genes
(mecA, blaZ, tet(M), tet(K), aac(6¢)-Ie–aph(2’)-Ia, aph(3’)-III, ant(6)-Ia, sat4, erm(B), lnu(A), dfr(G), and catpC221) were
identified by microarray and double mutations in the gyrA and grlA genes and a single mutation in the rpoB gene
were detected by sequence analysis. No differences were detected between MSSP and MRSP in the chlorhexidine
acetate (CHA) minimum inhibitory concentrations (MICs). However, two MSSP had elevated MIC to triclosan
(TCL) and one to benzalkonium chloride and ethidium bromide. One MSSP isolate harboured a qacA gene, while
in another a qacB gene was detected. None of the isolates harboured the sh-fabI gene. Three of the biocide
products studied had high bactericidal activity (Otodine, Clorexyderm Spot Gel, Dermocanis Piocure-M),
while Skingel failed to achieve a five log reduction in the bacterial counting. S. pseudintermedius have become a
serious therapeutic challenge in particular if methicillin- resistance and/or multidrug-resistance are involved.
Biocides, like CHA and TCL, seem to be clinically effective and safe topical therapeutic options.
Introduction
Methicillin-resistant Staphylococcus pseudintermedius(MRSP) has emerged recently and has become a se-
rious therapeutic challenge for veterinarians, due to multi-
drug resistance.9,12,24,30 They are a major cause of skin and
urinary tract, and hospital acquired infections in dogs and
cats.12,30 Originally, two major MRSP clones were found
to spread in Europe (ST71-t02-SCCmec II-II) and North
America (ST68-t06-SCCmec V).4,24,30 Although more recent
reports have yet identified other S. pseudintermedius line-
ages carrying the mecA gene,11,22 methicillin-susceptible S.
pseudintermedius (MSSP) tend to be genetically more diverse
than MRSP.2,4
In addition to the mecA gene, MRSP isolates usually
have mutations in the gyrase and topoisomerase genes,
conferring resistance to fluoroquinolones10 and several other
genes, which mediate resistance to gentamicin, kanamycin,
erythromycin, clindamycin, streptomycin, tetracycline and
trimethoprim.12,30 Resistance to rifampicin and chloram-
phenicol has also been reported in some MRSP strains.12,17,30
This pattern of multidrug resistance is normally in contrast to
what happens with MSSP.12 Resistance to ampicillin and
penicillin is often reported in MSSP isolates, but they are
usually susceptible to the other antimicrobial classes.12 Yet,
treatment of MRSP infections is based on the same principles
as MSSP infections, usually involving systemic and/or topic
therapy. The difference lies on the number of antimicrobial
options available for a successful treatment. While there are
several antimicrobial options for MSSP therapy, some of
the antimicrobials used for the treatment of MRSP infections
are not licensed for veterinary use and considered ‘‘critically
important’’ for human medicine by the World Health
Organization.32 Other antimicrobials, like rifampicin and
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chloramphenicol, are potentially toxic and have suboptimal
pharmacological features for small animals.12,17 For this
reason, topical therapy, especially antiseptic preparations,
has gained a renewed interest. Biocide topical therapy can be
used as solo or as an adjuvant for the treatment of skin, ear
and wound infections.12 Previous studies have assessed the
in vitro efficacy of biocides through determination of mini-
mum inhibitory concentrations (MICs) and/or minimum
bactericidal concentrations.15,27,33 Although the determina-
tion of MICs is important for the detection of efflux pheno-
types (especially through detection of the ethidium bromide
[EtBr] MICs) the in vitro efficacy of a biocide, as recommended
by the Scientific Committee on Emerging and Newly Identi-
fied Health Risks (SCENIHR), should involve the use of a
neutralising agent or by the removal of the biocide.25 This is
important to avoid an over-estimation of the lethality of the
biocide compound, since biocides are usually in contact with
the bacteria only for a brief period of time.
To date, only a few studies have determined biocide sus-
ceptibility of S. pseudintermedius. This study compares the
clonality, antimicrobial and biocide susceptibility of MSSP
and MRSP that have been isolated from the nasal cavities of
healthy animals as well as from infection sites.
Materials and Methods
Strain collection
Twenty MRSP and twenty MSSP strains isolated between
2007 and 2011 were included in the study. The isolates were
collected at the Laboratory of Antimicrobial and Biocide
Resistance, FMV-UTL, which receives samples from the
Veterinary Teaching Hospital of FMV-UTL and private
practices covering the area of the Lisbon region. Five isolates
were from cats and 35 were from dogs. These included
clinical infection (urinary tract infection, n = 6; skin infection,
n = 10; ear infection, n= 5; surgical site infection, n= 1) and
nasal colonization isolates (n = 18).
Multi-locus sequence typing, spa and SCCmec typing
Isolates were characterized by Multi-locus sequence typ-
ing (MLST) using the MLST scheme of Bannoehr et al.,2
which is based on five housekeeping genes ( pta, cpn60, tuf,
16S rRNA and agrD),24 and also by the newly described
S. pseudintermedius MLST scheme, which is based on seven
housekeeping genes (ack, cpn60, fdh, pta, purA, sar, tuf).27
MRSP isolates were also characterized by spa and SCCmec-
typing. spa-typing was performed by sequencing the poly-
morphic region of protein A gene (spa) and spa types were
assigned according to previously proposed guidelines.24
SCCmec types were determined using the multiplex PCR 1
and the multiplex PCR 2 according to Kondo and collabo-
rators.18 In multiplex PCR 1, the presence of mecA was con-
firmed and the ccr gene complex was determined. In
multiplex PCR 2, the mec class complex was assessed.18 The
combination of the type ccr and mec complex was used to
consign SCCmec types. SCCmec II-III was identified by PCR
using primers described previously.23
eBURST analysis
Predicted lines of evolutionary descent in our collection of
MRSP and MSSP isolates were identified using the eBURST
algorithm (http://eburst.mlst.net). eBURST identified groups
of related sequence types (ST) by assigning all members that
shared identical alleles at four of the five gene loci (MLST-5
scheme) or six of the seven gene loci (MLST-7 scheme) with
at least one other member of the group.2 The founding ST of
each group was determined by the ST with the greatest
number of single locus variants (SLV).28 Subgroups were
defined by the existence of at least three SLV.
Pulsed-field gel electrophoresis
The S. pseudintermedius strains were compared for their
genetic relatedness by SmaI macrorestriction, using a previ-
ously described protocol.9 The SmaI fragment patterns were
analysed with BioNumerics (Applied Maths, Kortrijk, Bel-
gium), the similarities between profiles were calculated using
the Dice coefficient with a maximum position tolerance of
1.0%. The patterns were clustered by using the unweighted
pair group method with arithmetic averages based on a
similarity cut-off value of 80%.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the disk
diffusion method and according to the Clinical and Labora-
tory Standards Institute guidelines.7 The antibiotic resistance
genes were detected using the custom-made microarray
AMR+ve-2 (Alere GmbH, Cologne, Germany)24 and by
PCR.19,24 Mutations in the quinolone resistance-determining
region (QRDR) of gyrA and grlA were determined by PCR
using the following primers: gyrA_pseudFW 5¢-ATGAGTG
TTATCGTATCTCGTGC-3¢, gyrA_pseudRV 5¢-GAACCGAA
GTTACCTTGACCAT-3¢, grlA_pseudFW 5¢-AATACGTAT
GATAAACATTTTCG-3¢ and grlA_pseudRV 5¢-TCGGTAT-
CATCATAGTTCGG-3¢, respectively. Mutations in the ri-
fampicin resistance-determining region (RRDR) within the
rpoB gene of the rifampicin-resistant isolates were amplified
by PCR and sequenced as described previously.17
Biocide susceptibility
MICs were determined for the following antiseptics and
dye: chlorhexidine acetate (CHA), benzalkonium chloride
(BAC), triclosan (TCL) and EtBr. EtBr MIC determination is a
simple screening procedure for identifying strains, which
have increased expression of efflux pump genes or an efflux
phenotype.8 CHA, BAC and TCL were determined to further
characterize any efflux phenotype. The bactericidal activity (at
5 minutes and 20C) of four commercial dermatological
preparations (Otodine, Clorhexyderm Spot Gel, Dermoca-
nis Piocure-M and Skingel) was determined against MRSP
and MSSP according to the document NF EN 1040–Essai
quantitatif de suspension pour l’e´valuation de l’activite´ bac-
tericide de base des antiseptiques et des de´sinfectants chimi-
ques.1 Both Otodine and Clorhexyderm Spot Gel contain CHA
(0.15% and 0.3%, respectively), Dermocanis Piocure-M has
TCL (0.3%) and Skingel contains zinc oxide (10%). The full
formulation of the biocide products can be found at the
manufacture’s website (www.icfpet.it). Briefly, isolates were
grown on a solid medium for 24 hours at 37C and suspended
on a diluent to 1.5–5· 108 colony-forming units/ml. Each cell
suspension was inoculated into water containing the biocides
and was exposed for 5 minutes, as recommended by NF1040.
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To inactivate the biocides, the bacteria-biocide mixture was
transferred into the neutralization medium (phosphate buffer
0.25mmol/L pH 7.2) for 5 minutes. Then the mixture was
inoculated onto Tryptone-Soy agar plates without the bio-
cides. Bacteria growth was observed after incubation at 37C
for 24 hours. Bactericidal activity was defined as a logarith-
mical reduction on bacterial cell counts of at least five loga-
rithms. S. aureus ATCC 29213 and S. aureus ATCC 6538 were
used as quality controls. The detection of efflux genes qacA/B,
smr, qacG, qacH and qacJ was performed by PCR.3,8 The qacA/B
positive amplicons were sequenced. The detection of sh-fabI
was performed by PCR using primers described recently by
Ciusa et al., using S. aureus strain M0091 as a positive control.6
Results
Strain characterization by genotyping
The epidemiological, genotypic and phenotypic traits of
the forty MRSP and MSSP isolates under study are shown in
Table 1. MLST-7 allowed a better discrimination than MLST-
5 and further distinguished among strains (Table 1). The
MSSP strains were divided into 19 or 24 different STs ac-
cording to the MLST-5 and MLST-7 schemes, respectively
(see Table 1). Two novel cpn60 alleles (alleles 43 and 44, ac-
cession numbers JX976294 and JX982108, respectively) and
four novel pta alleles (alleles 32, 34, 35 and 36, accession
numbers JX982110, KC438371, JX982112 and JX987962, re-
spectively) were found. Using the MLST-5 scheme, 17 MRSP
belonged to ST71, two belonged to ST97 and one to ST2 (Fig.
1a). When applying the new MLST-7 scheme only 14 MRSP
ST71 isolates were assigned to the ST71, and three being as-
signed to ST203; two ST97 were subdivided into ST196 and
ST213, and ST2 was assigned to ST195. Yet ST203 and ST195
belonged to the clonal complex (CC) 71, as detected by the
eBURST analysis (Fig. 1b). Likewise ST196 and ST213 differed
only by one allele and belonged to CC196 (Fig. 1b). Pulsed-field
gel electrophoresis (PFGE) analysis, based on a similarity cut-off
value of 80%, revealed two major clusters of MRSP, one con-
taining the CC71 isolates and the other cluster having the
CC196 strains (Fig. 2). The MRSP isolate ST195 was non-type-
able by SmaI restriction PFGE. Similar to MLST results, PFGE
analysis revealed that the MSSP isolates were genetically more
diverse (Fig. 3). eBURST analysis performed in our collection of
MRSP and MSSP isolates was very different when using the
MLST-5 and MLST-7 schemes. When applying the MLST-5
scheme eBURST showed that the S. pseudintermedius isolates
belonged to very similar STs, only differing in one or two of the
five loci examined (Fig. 3a). As expected, eBURST analysis us-
ing the MLST-7 scheme had very different results, with only a
few STs relating with another (Fig. 1b) and the MSSP being
singletons (data not shown).
Antimicrobial susceptibility and resistance genes
Antimicrobial resistance patterns of the S. pseudintermedius
isolates are shown in Table 1. All MRSP isolates were resis-
tant to erythromycin, clindamycin, fluoroquinolones (cipro-
floxacin, enrofloxacin, moxifloxacin, norfloxacin, ofloxacin
and pradofloxacin), trimethoprim/sulfamethoxazole, genta-
micin, tobramycin, kanamycin and streptomycin. Ad-
ditionally 17 MRSP isolates had tetracycline-resistance, one
had chloramphenicol resistance and one was resistant to ri-
fampicin. MSSP were more susceptible than MRSP strains to
the tested antibiotics. Eight strains were susceptible to all
antibiotics. All isolates were susceptible to fluoroquinolones.
Ampicillin and penicillin resistance was present in nine
MSSP strains, while eight were resistant to tetracycline. Two
MSSP strains were resistant to erythromycin, clindamycin,
kanamycin, streptomycin and chloramphenicol and one was
resistant to trimethoprim/sulfamethoxazole. Resistances
were attributed to the presence of the penicillin binding
protein gene mecA (all b-lactams), the b-lactamase gene
blaZ (penicillin), the tetracycline resistance genes tet(M)
and tet(K), aminoglycoside acetyltransferase and phospho-
transferase gene aac(6¢)-Ie–aph(2’)-Ia (all aminoglycosides
except streptomycin), phosphotransferase gene aph(3’)-III
(kanamycin, neomycin, paromomycin, amikacin, gentamicin
B), streptomycin adenyltransferase gene ant(6)-Ia, the mac-
rolide, lincosamide and streptogramin B 23S rRNA methyl-
ase gene erm(B), the lincosamide nucleotidyltransferase
lnu(A), the chloramphenicol acetyltransferase gene catpC221,
the trimethoprim-resistance dihydrofolate reductase gene
dfr(G). Two amino acid substitutions (S84L of GyrA and
S80I of GrlA) were found in the QRDR of fluoroquinolone-
resistant isolates. The rifampicin-resistant isolate had an
A522D substitution in the RRDR. One MSSP strain har-
boured a lnu(A) gene but was not resistant to clindamycin.
Biocide susceptibility, qac and sh-fabI genes
Fourteen and six MRSP isolates presented an MIC of 1mg/L
and 2mg/L of BAC, respectively (Table 2). Eighteen MSSP
isolates had anMICof 0.5mg/L toBAC (Table 2).AllMRSP and
MSSP strains had an MIC of 1mg/L to CHA. All MRSP iso-
lates and 18 MSSP had an MIC to TCL of £0.003mg/L, while
one isolate had an MIC of 0.125mg/L. None of the isolates car-
ried the recently described TCL resistance gene sh-fabI. MIC to
EtBr were £4mg/L, except for one isolate, which showed an
EtBrMIC of 32mg/L (Table 2). This MSSP isolate (FMV20A/08)
had an MIC of four to BAC and harboured the quaternary com-
pound resistance gene qacA. AnotherMSSP isolate (FMV750/10)
had the qacB gene but no detectable efflux mechanisms. All
MRSP isolates were negative for the efflux genes tested.
Three preparations, Otodine, Clorexyderm Spot Gel and
Dermocanis Piocure-M, had bactericidal activity against all
MRSP and MSSP isolates. However, Skingel could not
achieve a five log reduction of the bacterial count.
Discussion
Methicillin resistance have only been recently reported in
S. pseudintermedius strains, but their capacity to resist to an-
timicrobial therapy is already a worldwide concern.23,30 ST71
was the predominant clone emphasizing its spread. The use
of the new MLST scheme based on seven housekeeping
genes allowed distinguishing between some of the strains of
the CC71, revealing new ST195 and ST203. ST71 has been
previously described among MRSP colonization isolates
from dogs in Portugal;9 however, this is the first report of
MRSP ST196 and ST213 (CC196), which are not related to
CC71. MSSP isolates, instead, were more genetically diverse,
with all MSSP isolates corresponding to a single ST. These
findings are in agreement with two previous reports,2,4
where MRSP isolates were restricted to a small number of ST,
while MSSP strains revealed substantial clonal diversity.
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However, two recent reports found the mecA gene in a
considerable high number of ST,11,22 indicating that different
lineages of S. pseudintermedius can acquire SCCmec elements.
Only two types of SCCmec elements were detected among
the MRSP from Portugal, namely SCCmec II-III in isolates of
CC71 and SCCmec V in isolates of CC196.
Antimicrobial resistance is typically very different be-
tween MRSP and MSSP. While MRSP tend to be multidrug-
resistant, MSSP are usually only resistant to ampicillin and
penicillin, due to the presence of the blaZ gene.12 Accordingly
we found a multidrug resistant pattern in all MRSP isolates.
However, two MSSP strains were also resistant to more than
three antimicrobial classes, categorizing these strains as
multidrug-resistant. Some studies have also identified mul-
tidrug-resistance among MSSP isolates.13,14,29 Nevertheless,
in the majority of the studies MSSP strains were only resis-
tant to ampicillin and one additional antimicrobial class.12,30
Several antimicrobial resistance genes have been detected in
S. pseudintermedius strains16 and our strains exhibit the same
genes as detected before. Contrary to the study of Vanni
and colleagues,31 which only detected resistance to second-
and third-generation fluoroquinolones in S. pseudintermedius
isolates, our fluoroquinolone-resistant S. pseudintermedius
strains were resistant to second (ciprofloxacin, enrofloxacin,
norfloxacin, and ofloxacin), third generation (pradofloxacin),
and fourth generation (moxifloxacin) fluoroquinolones. The
same authors argued that a single alteration in grlA would be
sufficient to confer resistance against older fluoroquinolones
but an additional mutation in gyrA was required for resis-
tance to new fluoroquinolones to develop, as it occurs in
S. aureus and coagulase-negative staphylococci isolates.31
Accordingly, our strains presented resistance to all the
fluoroquinolones tested, including moxifloxacin, due to the
presence of mutations at both the gyrA and grlA genes.
Surprisingly there was a major difference between the
mechanisms of resistance to tetracycline: tet(K) genes were
only identified among MRSP strains, while tet(M) was only
found among MSSP isolates. The tet(K) gene codes for an
efflux pump of the major facilitator superfamily and is usu-
ally found on small plasmids.16 In contrast, tet(M) codes for
ribosome protective proteins and has been identified as part
of conjugative transposons, such as Tn916 and Tn1545.16
Other studies have identified tet(M) in other MRSP strains,
yet in MRSP ST71 only tet(K) has been detected, which could
indicate that this clone has a preference for plasmid-borne
tetracycline resistance rather than tet transposon-borne
genes.
Rifampicin resistance in MRSP isolates has been described
previously.17 Mutation at rpoB codon 522 was identified in a
clinical isolate after treatment of a clinical infection with a
combination of rifampicin and tetracycline.17 Our rifampicin-
FIG. 1. Schematic diagram of the clonal relatedness of
Staphylococcus pseudintermedius sequence types (ST) predicted
by eBURST analysis using the multilocus sequence typing
(MLST)-5 (a) and the MLST-7 (b) schemes, respectively. Each
black dot represents an ST and the dot size is proportional to
the number of isolates of that ST. The square corresponds to
the predicted group founder and ST97 and ST17 represent
predicted subgroup founders (a). Single-locus variants are
linked by lines. Methicillin-susceptible S. pseudintermedius
(MSSP) singletons are not shown in this figure.
FIG. 2. Dendogram of chromosomal DNA digested with SmaI of methicillin-resistant S. pseudintermedius strains and
relatedness to ST. Pulsed-field cluster determination using a Dice similarity coefficient with an optimization of 1% and a band
tolerance setting of 1%.
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resistant MRSP isolate came from a dog with pyoderma,
with no previous recorded history of rifampicin treatment.
As stated before,17 the observed rpoB mutation could have
occurred spontaneously or the isolate could have been
transferred from a previously treated dog.
Since the discovery of multidrug-resistant S. pseudinter-
medius there has been an increasing interest in additional
bactericidal therapeutics, other than the use of antibiotics.
Susceptibility to biocides has now become an urgent matter.
In this study, we compared the in vitro efficacy of four com-
mercial biocides using the methodology recommended by the
SCENIHR.25 At the same time we performed the determina-
tion of the biocide MICs to detect decreased susceptibility
related to efflux activity. Only one strain showed higher EtBr
MIC values compared to the wild-type S. aureus ATCC6538
and harboured a qacA gene. The qacB-positive MSSP strain
(FMV750/10) did not show any decreased susceptibility re-
lated to efflux activity. The same strain also had a lnu(A)
gene but was not clindamycin-resistant. This could indicate a
failure in the regulation and/or induction mechanism of
these genes. However, further studies are needed to address
this issue. To the best of our knowledge, this is the first
description of qacA and qacB genes among S. pseudintermedius
strains.
The efficacy of chlorhexidine has been previously tested
in vitro and also in vivo. In our study we found an MIC value
of 1mg/L for all MRSP and MSSP strains, which is lower
than the MIC range found by Valentine and colleagues29 (4–
16mg/L) but within the range found by Murayama et al.,
(0.5–1mg/L).20 This latter study could not detect any qacA/B
or smr genes. This MIC of 1mg/L is lower than the clinically
used concentrations and so it is not surprising that Otodine
and Clorexyderm Spot Gel were efficient at killing the MSSP
and MRSP strains. There was no difference in the efficacy of
the chlorhexidine products, but previous studies have
suggested that products with higher concentrations of CHA
(3%–4%) were more effective than products with a lower
concentration (2%–2.5%).15,33 Still, an in vivo study comparing
the use of two different chlorhexidine formulations (CHA 2%
and chlorhexidine gluconate 4%) for the treatment of cepha-
lexin-resistant S. pseudintermedius pyoderma found no differ-
ences in the efficacy of the two shampoos.21
QAC efflux pumps are known to extrude BAC;8 however,
the MICs previously found in other studies are still below the
typically used concentrations of 10 g/L.29 In our study we
FIG. 3. Dendogram of chromosomal DNA digested with SmaI of MSSP strains and relatedness to ST. Pulsed-field cluster
determination using a Dice similarity coefficient with an optimization of 1% and a band tolerance setting of 1%.
Table 2. MICs of Dyes (Ethidium Bromide)
and Biocides (Benzalkonium Chloride,
Chlorhexidine Acetate and Triclosan), and Genes
Associated with Efflux Phenotype
MICs (mg/L)
Number of strains BAC CHA EtBr TCL
Efflux
genes
MRSP
10 1 1 2 £ 0.003 -
3 2 1 4 £ 0.003 -
3 2 1 2 £ 0.003 -
2 1 1 4 £ 0.003 -
1 1 1 1 0.007 -
1 1 1 2 0.007 -
MSSP
11 0.5 1 1 £ 0.003 -
6 0.5 1 2 £ 0.003
1 4 1 32 0.125 qacA
1 0.5 1 2 £ 0.003 qacB
1 1 1 2 4 -
S. aureus ATCC 6538 1 1 8 £ 0.003 -
BAC, benzalkonium chloride; CHA, clorhexidine acetate; EtBr,
ethidium bromide; MICs, minimum inhibitory concentrations;
MRSP, methicillin-resistant Staphylococcus pseudintermedius; MSSP,
methicillin-resistant S. pseudintermedius; TCL, triclosan.
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detected two strains harbouring qac genes but their MICs
were also below the in-use concentration. However, even if
the strains appeared susceptible in vitro in the presence of
these genes, they may challenge biocide therapy in vivo.
None of the strains with high MIC to TCL carried the
newly described plasmid-mediated TCL resistance gene sh-
fabI.6 The higher MIC values in the two MSSP strains, and the
absence of the sh-fabI gene may indicate that another mech-
anism is present, probably mutations in the original fabI
gene, which have been previously described in S. aureus and
S. haemolyticus strains.6 A recent study assessed the MIC of
TCL against MRSP and MSSP strains.29 The authors con-
cluded that TCL demonstrated excellent activity against all
bacterial isolates with a MIC £0.5mg/L.29 In this study, we
detected one MSSP strain with a MIC of 4mg/L to TCL,
which is higher compared to the wild-type S. aureus
ATCC6538 (MIC £ 0.003) and the other S. pseudintermedius
strains. However, when testing the bactericidal activity of
Dermocanis Piocure-M, a commercial product with a TCL
concentration 750 times higher than the MIC, no bacterial
growth was observed. Likewise, the MSSP strain presenting
an efflux phenotype, when challenged with three commercial
products containing biocides was also not able to survive. This
could mean that although some strains have efflux mecha-
nisms to biocides, they will not be able to survive if the bio-
cides are used at the correct concentration and exposure time.
Skingel is an antiphlogistic product, containing zinc ox-
ide, which is known to have antibacterial properties.26 Zinc
oxide has been shown to reduce S. aureus viability and bio-
film formation when incorporated as a nanoparticle into
films of polyvinyl chloride (endotracheal tubes and cathe-
ters).26 However, Skingel was not able to achieve a five-log
reduction in the bacterial cell number and so had no bacte-
ricidal effect on S. pseudintermedius strains. Zinc resistance
has been detected in S. aureus strains of animal origin and
has been strongly associated with methicillin resistance.5
Further studies are needed to evaluate heavy metal resis-
tance in S. pseudintermedius.
S. pseudintermedius have become a serious therapeutic
challenge and new MRSP lineages are emerging in several
countries, including Portugal. Although multidrug-resis-
tance is more common in methicillin-resistant strains, some
of the methicillin-susceptible strains also exhibited multi-
drug-resistance profile. The use of biocides, like CHA and
TCL, seems to be a clinically effective and a safe topical
therapeutic option.
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